CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP).

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass.

ATLANTA , Feb. 12, 2025 /PRNewswire/ -- The Board of Directors of Southern Company today announced the election of James O. (Jimmy) Etheredge as an independent director, effective Apr. 1, 2025.

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.

Alcohol is generally inelastic as prices rise; demand tends to remain the same. However, this doesn't mean consumers can't trade down or switch types of alcohol.

All-in-one dive computer and smartwatch adds a bright AMOLED display for easy reading at any depth plus tools for life in and out of the water OLATHE, Kan. , Feb. 12, 2025 /PRNewswire/ -- Garmin (NYSE: GRMN) today announced the Descent™ G2 , a rugged watch-style dive computer with features to help divers explore both their underwater and topside worlds.

Phase III trial to assess the efficacy and safety of EscharEx ® for debridement and facilitation of active wound closure

Dubai and Islamabad, February 12 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or the “Group”), today announces that it has been shortlisted for two Global Mobile (GLOMO) Awards at the upcoming MWC 2025.

Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II Enroll ed more than 7 00 P atients to D ate; Enrollment Completion Expected in March 202 5 , with T op- L ine Results Anticipated in Second Quarter of 2025 Company Completed Private Placement of Up to $41 Million; Proceeds and Exercise of Data-Triggered Warrant s Expected to Extend Cash Runway Beyond Potential NDA Approval Conference Call S cheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Feb. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” …

BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK) cell therapy, INKmune™, in a Phase I/II trial (the “CaRe PC” trial) for men with metastatic castration-resistant prostate cancer (mCRPC). The Company is pleased to announce completion of the third and highest dose cohort of the Phase I portion of the trial allowing opening of the Phase II high dose cohort.

New York, NY, Feb. 12, 2025 (GLOBE NEWSWIRE) -- FOURTH QUARTER Total revenue, including billable expenses, was $2.9 billion Revenue before billable expenses ("net revenue") was $2.4 billion, with organic decrease of -1.8% Reported net income was $344.5 million Adjusted EBITA before restructuring charges and deal costs was $591.2 million with margin of 24.3% on revenue before billable expenses Diluted earnings per share of $0.92 as reported and $1.11 as adjusted FULL YEAR Total revenue, including billable expenses, was $10.7 billion Revenue before billable expenses ("net revenue") was $9.2 billion, with organic growth of 0.2% Reported net income was $689.5 …

TUS+VEN+AZA triplet achieves Cycle 1 complete remission (CR) in TP53-mutated/CK AML TUS+VEN+AZA triplet achieves Cycle 1 complete remissions in FLT3-wildtype AML patients TUS+VEN+AZA triplet shows favorable safety with no alteration of VEN and AZA dosing PK levels of TUS in the triplet remain equivalent to levels as TUS or TUS+VEN therapy SAN DIEGO and TORONTO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today reported promising early safety and response results from newly diagnosed acute myeloid leukemia (AML) patients dosed in Aptose's Phase 1/2 TUSCANY trial …

GREENWICH, Conn., Feb. 12, 2025 (GLOBE NEWSWIRE) -- QXO, Inc. (NYSE: QXO) announced today that it has obtained antitrust clearance in both the U.S. and Canada for its acquisition of Beacon Roofing Supply, Inc. (Nasdaq: BECN), paving the way for QXO to close the transaction quickly.

– Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 –

SPARTANBURG, S.C., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Denny's Corporation (the "Company") (NASDAQ: DENN), owner and operator of Denny's Inc. ("Denny's") and Keke's Inc. ("Keke's") today reported results for its fourth quarter and full year ended December 25, 2024 and provided a business update on the Company's operations.

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close.

LONDON and NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Wilmington Trust and AccessFintech have announced a new collaboration that automates and streamlines loan lifecycle management using the Synergy platform. This effort drives real-time data transparency and collaboration, significantly reducing discrepancies and resolution times among various organizations across the loan market.

Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into the second half of 2026 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $105 million, before deducting placement agents' fees and other expenses.

MALMÖ, Sweden, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Oatly Group AB (Nasdaq: OTLY) (“Oatly” or the “Company”), the world's original and largest oat drink company, today announced financial results for the fourth quarter and twelve months ended December 31, 2024. Jean-Christophe Flatin, Oatly's CEO, commented, “Over the past two years, we have executed a significant transformation of our company.

NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period").